Market Overview

Bristol-Myers Squibb Says Orencia Approved by EU

Related BMY
Bristol-Myers Squibb Says FDA-Approved ORENCIA Is Available For Adults With Moderate To Severe Rheumatoid Arthritis
Jim Cramer Shares His Thoughts On Bristol-Myers Squibb And The RNC
5 Big Drugmakers Reporting Earnings Next Week (Investor's Business Daily)

Bristol-Myers Squibb announced today that the European Commission has granted marketing authorisation for the subcutaneous formulation of ORENCIA ® (abatacept), in combination with methotrexate (MTX), for the treatment of adults with moderate to severe active rheumatoid arthritis (RA).

Posted-In: News FDA


Related Articles (BMY)

View Comments and Join the Discussion!